What Key Growth Drivers Are Shaping The Oncolytic Adenovirus Market Forecast Toward $181.71 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Oncolytic Adenovirus Market?
The market for oncolytic adenovirus has seen significant expansion in recent years. Its size is projected to increase from $122.31 billion in 2024 to $132.49 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. Factors such as a rise in the number of cancer cases, escalating demand for specific cancer treatments, increased research and development funding, enhanced delivery techniques, and regulatory approvals have contributed to its growth over the historic period.
The market for oncolytic adenovirus is projected to expand significantly in the forthcoming years. It is set to soar to $181.71 billion by 2029, with a compound annual growth rate (CAGR) of 8.2%. The projected growth during the forecast period can be traced back to increasing cancer cases, the expansion of combination treatments, regulatory improvements, technological advancements in virus engineering, and more investment in oncology research. Dominant trends for the forecast period involve progress in viral engineering techniques, sophisticated drug delivery systems, improvements in tumor targeting accuracy, advanced combinations of immunotherapies, and enhancements in patient monitoring and diagnostic tools.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Oncolytic Adenovirus Market?
The oncolytic adenovirus market is anticipated to expand due to the escalating prevalence of cancer. Cancer, a condition marked by unregulated cell proliferation which can invade other body parts, is seeing an increase mainly induced by aging populations, lifestyle influences, environmental factors, genetic susceptibilities, and enhanced detection techniques. Oncolytic adenovirus is gaining prominence for its ability to uniquely target and destroy cancer cells, making it a potent solution to counter the rising incidence of cancer. For example, the National Cancer Institute (NCI), a US government agency, reported in May 2024, nearly 20 million fresh cancer cases and 9.7 million fatalities globally, and is projecting these numbers to surge to 29.9 million cases and 15.3 million deaths by 2040. Moreover, based on 2023 data from the Australian Bureau of Statistics, a government agency in Australia, cancer was found in 1.8% of the Australian population, with men (2.1%) being slightly more impacted than women (1.6%), notably those above 75 years of age. Hence, the upward trend of cancer is catalyzing the growth in the oncolytic adenovirus market.
What Are The Key Segment Trends Observed In The Oncolytic Adenovirus Market?
The oncolytic adenovirusmarket covered in this report is segmented –
1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types
2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications
3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes
Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based
3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses
What Strategic Shifts And Innovations Are Influencing The Oncolytic Adenovirus Market?
Major companies in the oncolytic adenovirus market are advancing combination therapies like VCN-01, which pairs oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve outcomes. VCN-01 is engineered to selectively infect and kill cancer cells while increasing chemotherapy efficacy. For example, in May 2024, Theriva Biologics, a US clinical-stage immuno-oncology company, announced FDA Fast Track Designation for VCN-01 used alongside gemcitabine and nab-paclitaxel to treat metastatic pancreatic adenocarcinoma. VCN-01 targets tumor cells and disrupts the tumor stroma, a major barrier to effective treatment.
Who Are The Leading Companies Driving The Oncolytic Adenovirus Market?
Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report
Which Region Is Forecasted To Lead The Oncolytic Adenovirus Market In The Coming Years?
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp
Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2025, By The Business Research Company
Virus Filtration Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report
Herpes Simplex Virus Treatment Global Market Report 2025
Human Papillomavirus Hpv Vaccine Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
